387 related articles for article (PubMed ID: 12201901)
1. Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms.
Mingomataj E; Priftanji A; Qirko E; Dinh QT; Fischer A; Peiser C; Groneberg DA
BMC Dermatol; 2002 Aug; 2():11. PubMed ID: 12201901
[TBL] [Abstract][Full Text] [Related]
2. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
3. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
5. Systemic and local reactions of bee venom immunotherapy in Iran.
Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
[TBL] [Abstract][Full Text] [Related]
7. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
Gawlik R; Glück J; Jawor B; Rogala B
Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
9. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
10. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
11. Hymenoptera sting anaphylactic reactions in the Mediterranean population of Albania.
Mingomataj E; Ohri D; Dhimitri V; Priftanji A; Qirko E; Pani L; Fischer TC; Dinh QT; Peiser C; Fischer A; Groneberg DA
J Investig Allergol Clin Immunol; 2003; 13(4):272-7. PubMed ID: 14989117
[TBL] [Abstract][Full Text] [Related]
12. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
Sturm G; Kränke B; Rudolph C; Aberer W
J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
[TBL] [Abstract][Full Text] [Related]
13. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Haeberli G; Brönnimann M; Hunziker T; Müller U
Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
[TBL] [Abstract][Full Text] [Related]
14. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
[TBL] [Abstract][Full Text] [Related]
15. Hymenoptera venom allergy.
Przybilla B; Ruëff F
J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines.
Fiedler C; Miehe U; Treudler R; Kiess W; Prenzel F
Int Arch Allergy Immunol; 2017; 172(3):167-172. PubMed ID: 28380475
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology.
Bousquet J; Müller UR; Dreborg S; Jarisch R; Malling HJ; Mosbech H; Urbanek R; Youlten L
Allergy; 1987 Aug; 42(6):401-13. PubMed ID: 3310714
[TBL] [Abstract][Full Text] [Related]
18. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
19. Hymenoptera venom allergy in humans.
Cichocka-Jarosz E
Folia Med Cracov; 2012; 52(3-4):43-60. PubMed ID: 24852686
[TBL] [Abstract][Full Text] [Related]
20. [Therapy control of specific hymenoptera venom allergy].
Aust W; Wichmann G; Dietz A
Laryngorhinootologie; 2010 Dec; 89(12):725-8. PubMed ID: 21132618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]